Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib in Neo-adjuvant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
NCT04455594Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Oct 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Status: unknown.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04455594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04455594.